Changes in 1746aa9: table1

				ATP10A.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_ATP10A.md]]

				ATP11C.md
			
          @@ -10,9 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description                            |

          -|:------:|:----:|---------------------------------------|

          -|![MCL](images/icons/MCL_tier2.png)   |2   |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|

          +[[include:table1_ATP11C.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ATP6V1B2.md
			
          @@ -10,9 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description            |

          -|:------:|:----:|-----------------------|

          -|![FL](images/icons/FL_tier1.png)    |1   |high-confidence FL gene[@okosunRecurrentMTORC1activatingRRAGC2016]|

          +[[include:table1_ATP6V1B2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ATR.md
			
          @@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re

           ## Relevance tier by entity

          -|Entity|Tier|Description                              |

          -|:------:|:----:|-----------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier2.png) |2   |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|

          +[[include:table1_ATR.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				AXDND1.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@gomezUltraDeepSequencingReveals2023]|

          +[[include:table1_AXDND1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				B4GALNT2.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_B4GALNT2.md]]

				BAI1.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@novakWholeexomeAnalysisReveals2015]|

          +[[include:table1_BAI1.md]]

				BAZ1A.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_BAZ1A.md]]

				BCAT2.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_BCAT2.md]]

				BCL10.md
			
          @@ -22,11 +22,7 @@ BCL10 missense mutations in the CARD domain and truncating mutations have distin

           ## Relevance tier by entity

          -|Entity|Tier|Description                           |

          -|:------:|:----:|--------------------------------------|

          -|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@spinaGeneticsNodalMarginal2016]|

          -|![DLBCL](images/icons/DLBCL_tier1.png)  |1[@xiaBCL10MutationsDefine2022]   |high-confidence DLBCL gene[@morinFrequentMutationHistonemodifying2011;@morinMutationalStructuralAnalysis2013]            |

          -|![FL](images/icons/FL_tier2.png)     |2   |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|

          +[[include:table1_BCL10.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BCL11A.md
			
          @@ -12,9 +12,7 @@ BCL11A (B-cell lymphoma/leukemia 11A) is a transcription factor involved in the 

           ## Relevance tier by entity

          -|Entity|Tier|Description                           |

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene            |

          +[[include:table1_BCL11A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BCL2L10.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|

          +[[include:table1_BCL2L10.md]]

				BCOR.md
			
          @@ -16,11 +16,7 @@ BCOR acts as a co-repressor of BCL6, and mutations in BCOR could impair its bind

           ## Relevance tier by entity

          -|Entity|Tier|Description               |

          -|:------:|:----:|--------------------------|

          -|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|

          -|![DLBCL](images/icons/DLBCL_tier1.png) |2   |low-confidence DLBCL gene|

          -|![MCL](images/icons/MCL_tier1.png)   |1   |high-confidence MCL gene  [@nadeuGenomicEpigenomicInsights2020]|

          +[[include:table1_BCOR.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BCR.md
			
          @@ -15,9 +15,7 @@ BCR (Breakpoint Cluster Region Protein) is one of [a number of genes](https://gi

           ## Relevance tier by entity

          -|Entity|Tier|Description                           |

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene            [@lohrDiscoveryPrioritizationSomatic2012]|

          +[[include:table1_BCR.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BIRC3.md
			
          @@ -10,12 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description                              |

          -|:------:|:----:|-----------------------------------------|

          -|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021]|

          -|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiAlterationBIRC3Multiple2011]|

          -|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@arthurGenomewideDiscoverySomatic2018]|

          -|![MCL](images/icons/MCL_tier1.png)   |1 | aSHM target and high-confidence MCL gene                 [@beaLandscapeSomaticMutations2013]|

          +[[include:table1_BIRC3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BIRC6.md
			
          @@ -15,11 +15,7 @@ BIRC6, as a negative regulator of non-canonical NF-κB signaling, is implicated 

           ## Relevance tier by entity

          -|Entity|Tier|Description                           |

          -|:------:|:----:|--------------------------------------|

          -|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene [@sarkozyMutationalLandscapeGray2021]|

          -|![DLBCL](images/icons/DLBCL_tier1.png)   |1   |high-confidence DLBCL gene          [@reddyGeneticFunctionalDrivers2017; @arthurGenomewideDiscoverySomatic2018]|

          -|![FL](images/icons/FL_tier1.png)      |1   |high-confidence FL gene               |

          +[[include:table1_BIRC6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BLM.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_BLM.md]]

				BMPR1A.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_BMPR1A.md]]

				BRAF.md
			
          @@ -17,11 +17,7 @@ Although mutations have also been reported in BL, due to [minimal support](BRAF#

           ## Relevance tier by entity

          -|Entity|Tier|Description                           |

          -|:------:|:----:|--------------------------------------|

          -|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|

          -|![DLBCL](images/icons/DLBCL_tier1.png) |1   |high-confidence DLBCL gene            [@tiacciBRAFMutationsHairycell2011]|

          -|![BL](images/icons/Tier2_BL.png)    |2   |Failed QC[@loveGeneticLandscapeMutations2012]|

          +[[include:table1_BRAF.md]]

           ## Warnings

				BRCA1.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|

          +[[include:table1_BRCA1.md]]

				BRCA2.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_BRCA2.md]]

				BRD4.md
			
          @@ -14,9 +14,7 @@ Due to [minimal support](BRD4#representative-mutation) in the original primary d

           ## Relevance tier by entity

          -|Entity|Tier|Description                           |

          -|:------:|:----:|--------------------------------------|

          -|![BL](images/icons/BL_tier2.png)    |3   |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

          +[[include:table1_BRD4.md]]

           ## Warnings

				BRINP3.md
			
          @@ -15,9 +15,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re

           ## Relevance tier by entity

          -|Entity|Tier|Description                              |

          -|:------:|:----:|-----------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier2.png) |2   |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|

          +[[include:table1_BRINP3.md]]

           ## Warnings

				BRSK1.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|

          +[[include:table1_BRSK1.md]]

				BSCL2.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_BSCL2.md]]

				BTAF1.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_BTAF1.md]]

				BTBD3.md
			
          @@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero

           ## Relevance tier by entity

          -|Entity|Tier|Description                              |

          -|:------:|:----:|-----------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier2.png) |2   |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_BTBD3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BTG1.md
			
          @@ -21,13 +21,7 @@ Another study demonstrated that specific BTG1 mutations afford germinal center (

           ## Relevance tier by entity

          -|Entity|Tier|Description                           |

          -|:------:|:----:|--------------------------------------|

          -|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|

          -|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@sarkozyMutationalLandscapeGray2021]|

          -|![DLBCL](images/icons/DLBCL_tier1.png) |1[@mlynarczykBTG1MutationYields2023; @delageBTG1InactivationDrives2023] | aSHM target and high-confidence DLBCL gene            [@morinFrequentMutationHistonemodifying2011]|

          -|![FL](images/icons/FL_tier1.png)    |1 | aSHM target and high-confidence FL gene               |

          -|![BL](images/icons/BL_tier2.png)    |2 | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@burkhardtClinicalRelevanceMolecular2022]|

          +[[include:table1_BTG1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BTG2.md
			
          @@ -16,11 +16,7 @@ BTG2 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) 

           ## Relevance tier by entity

          -|Entity|Tier|Description                           |

          -|:------:|:----:|--------------------------------------|

          -|![BL](images/icons/BL_tier2.png)    |3 | Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

          -|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene            [@morinFrequentMutationHistonemodifying2011]|

          -|![FL](images/icons/FL_tier1.png)    |1 | aSHM target and high-confidence FL gene               [@morinFrequentMutationHistonemodifying2011]|

          +[[include:table1_BTG2.md]]

           ## Warnings

				BTK.md
			
          @@ -11,10 +11,7 @@ One study reported BTK mutations in approximately 7% of FL and 11% of transforme

           ## Relevance tier by entity

          -|Entity|Tier|Description               |

          -|:------:|:----:|--------------------------|

          -|![DLBCL](images/icons/DLBCL_tier1.png) |1   |high-confidence DLBCL gene[@albuquerqueEnhancingKnowledgeDiscovery2017; @reddyGeneticFunctionalDrivers2017]|

          -|![FL](images/icons/FL_tier1.png)    |1   |high-confidence FL gene   [@krysiakRecurrentSomaticMutations2017]|

          +[[include:table1_BTK.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				C12orf35.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|

          +[[include:table1_C12orf35.md]]

				C16orf48.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![BL](images/icons/BL_tier2.png)|2|relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|

          +[[include:table1_C16orf48.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				C6orf103.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|

          +[[include:table1_C6orf103.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZNF296.md
			
          @@ -10,9 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description                            |

          -|:------:|:----:|---------------------------------------|

          -|![MCL](images/icons/MCL_tier2.png)   |2   |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|

          +[[include:table1_ZNF296]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

...	...	@@ -22,11 +22,7 @@ BCL10 missense mutations in the CARD domain and truncating mutations have distin
22	22
23	23	## Relevance tier by entity
24	24
25		-\|Entity\|Tier\|Description \|
26		-\|:------:\|:----:\|--------------------------------------\|
27		-\|![MZL](images/icons/MZL_tier1.png)\|1\|high-confidence MZL gene[@spinaGeneticsNodalMarginal2016]\|
28		-\|![DLBCL](images/icons/DLBCL_tier1.png) \|1[@xiaBCL10MutationsDefine2022] \|high-confidence DLBCL gene[@morinFrequentMutationHistonemodifying2011;@morinMutationalStructuralAnalysis2013] \|
29		-\|![FL](images/icons/FL_tier2.png) \|2 \|relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]\|
	25	+[[include:table1_BCL10.md]]
30	26
31	27	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
32	28

...	...	@@ -13,9 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-\|Entity\|Tier\|Description\|
17		-\|:------:\|:----:\|--------------------------------------\|
18		-\|![DLBCL](images/icons/DLBCL_tier3.png)\|3\|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]\|
	16	+[[include:table1_ATP10A.md]]
19	17
20	18
21	19

...	...	@@ -10,9 +10,7 @@ nocite: \|
10	10
11	11	## Relevance tier by entity
12	12
13		-\|Entity\|Tier\|Description \|
14		-\|:------:\|:----:\|---------------------------------------\|
15		-\|![MCL](images/icons/MCL_tier2.png) \|2 \|relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]\|
	13	+[[include:table1_ATP11C.md]]
16	14
17	15	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18	16

...	...	@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re
14	14
15	15	## Relevance tier by entity
16	16
17		-\|Entity\|Tier\|Description \|
18		-\|:------:\|:----:\|-----------------------------------------\|
19		-\|![DLBCL](images/icons/DLBCL_tier2.png) \|2 \|relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]\|
	17	+[[include:table1_ATR.md]]
20	18
21	19	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22	20

...	...	@@ -12,9 +12,7 @@ BCL11A (B-cell lymphoma/leukemia 11A) is a transcription factor involved in the
12	12
13	13	## Relevance tier by entity
14	14
15		-\|Entity\|Tier\|Description \|
16		-\|:------:\|:----:\|--------------------------------------\|
17		-\|![DLBCL](images/icons/DLBCL_tier1.png) \|1 \| aSHM target and high-confidence DLBCL gene \|
	15	+[[include:table1_BCL11A.md]]
18	16
19	17	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20	18

...	...	@@ -16,11 +16,7 @@ BCOR acts as a co-repressor of BCL6, and mutations in BCOR could impair its bind
16	16
17	17	## Relevance tier by entity
18	18
19		-\|Entity\|Tier\|Description \|
20		-\|:------:\|:----:\|--------------------------\|
21		-\|![MZL](images/icons/MZL_tier2.png)\|2\|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]\|
22		-\|![DLBCL](images/icons/DLBCL_tier1.png) \|2 \|low-confidence DLBCL gene\|
23		-\|![MCL](images/icons/MCL_tier1.png) \|1 \|high-confidence MCL gene [@nadeuGenomicEpigenomicInsights2020]\|
	19	+[[include:table1_BCOR.md]]
24	20
25	21	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
26	22

...	...	@@ -15,9 +15,7 @@ BCR (Breakpoint Cluster Region Protein) is one of [a number of genes](https://gi
15	15
16	16	## Relevance tier by entity
17	17
18		-\|Entity\|Tier\|Description \|
19		-\|:------:\|:----:\|--------------------------------------\|
20		-\|![DLBCL](images/icons/DLBCL_tier1.png) \|1 \| aSHM target and high-confidence DLBCL gene [@lohrDiscoveryPrioritizationSomatic2012]\|
	18	+[[include:table1_BCR.md]]
21	19
22	20	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23	21

...	...	@@ -10,12 +10,7 @@ nocite: \|
10	10
11	11	## Relevance tier by entity
12	12
13		-\|Entity\|Tier\|Description \|
14		-\|:------:\|:----:\|-----------------------------------------\|
15		-\|![PMBL](images/icons/PMBL_tier2.png)\|2\|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021]\|
16		-\|![MZL](images/icons/MZL_tier1.png)\|1\|high-confidence MZL gene[@rossiAlterationBIRC3Multiple2011]\|
17		-\|![DLBCL](images/icons/DLBCL_tier2.png) \|2 \| aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@arthurGenomewideDiscoverySomatic2018]\|
18		-\|![MCL](images/icons/MCL_tier1.png) \|1 \| aSHM target and high-confidence MCL gene [@beaLandscapeSomaticMutations2013]\|
	13	+[[include:table1_BIRC3.md]]
19	14
20	15	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21	16

...	...	@@ -15,11 +15,7 @@ BIRC6, as a negative regulator of non-canonical NF-κB signaling, is implicated
15	15
16	16	## Relevance tier by entity
17	17
18		-\|Entity\|Tier\|Description \|
19		-\|:------:\|:----:\|--------------------------------------\|
20		-\|![PMBL](images/icons/PMBL_tier1.png)\|1\|high-confidence PMBL/cHL/GZL gene [@sarkozyMutationalLandscapeGray2021]\|
21		-\|![DLBCL](images/icons/DLBCL_tier1.png) \|1 \|high-confidence DLBCL gene [@reddyGeneticFunctionalDrivers2017; @arthurGenomewideDiscoverySomatic2018]\|
22		-\|![FL](images/icons/FL_tier1.png) \|1 \|high-confidence FL gene \|
	18	+[[include:table1_BIRC6.md]]
23	19
24	20	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25	21

...	...	@@ -17,11 +17,7 @@ Although mutations have also been reported in BL, due to [minimal support](BRAF#
17	17
18	18	## Relevance tier by entity
19	19
20		-\|Entity\|Tier\|Description \|
21		-\|:------:\|:----:\|--------------------------------------\|
22		-\|![MZL](images/icons/MZL_tier1.png)\|1\|high-confidence MZL gene\|
23		-\|![DLBCL](images/icons/DLBCL_tier1.png) \|1 \|high-confidence DLBCL gene [@tiacciBRAFMutationsHairycell2011]\|
24		-\|![BL](images/icons/Tier2_BL.png) \|2 \|Failed QC[@loveGeneticLandscapeMutations2012]\|
	20	+[[include:table1_BRAF.md]]
25	21
26	22	## Warnings
27	23

...	...	@@ -14,9 +14,7 @@ Due to [minimal support](BRD4#representative-mutation) in the original primary d
14	14
15	15	## Relevance tier by entity
16	16
17		-\|Entity\|Tier\|Description \|
18		-\|:------:\|:----:\|--------------------------------------\|
19		-\|![BL](images/icons/BL_tier2.png) \|3 \|Retired, Failed QC[@loveGeneticLandscapeMutations2012]\|
	17	+[[include:table1_BRD4.md]]
20	18
21	19	## Warnings
22	20

...	...	@@ -15,9 +15,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re
15	15
16	16	## Relevance tier by entity
17	17
18		-\|Entity\|Tier\|Description \|
19		-\|:------:\|:----:\|-----------------------------------------\|
20		-\|![DLBCL](images/icons/DLBCL_tier2.png) \|2 \|relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]\|
	18	+[[include:table1_BRINP3.md]]
21	19
22	20	## Warnings
23	21

...	...	@@ -21,13 +21,7 @@ Another study demonstrated that specific BTG1 mutations afford germinal center (
21	21
22	22	## Relevance tier by entity
23	23
24		-\|Entity\|Tier\|Description \|
25		-\|:------:\|:----:\|--------------------------------------\|
26		-\|![MZL](images/icons/MZL_tier1.png)\|1\|high-confidence MZL gene\|
27		-\|![PMBL](images/icons/PMBL_tier1.png)\|1\|high-confidence PMBL/cHL/GZL gene[@sarkozyMutationalLandscapeGray2021]\|
28		-\|![DLBCL](images/icons/DLBCL_tier1.png) \|1[@mlynarczykBTG1MutationYields2023; @delageBTG1InactivationDrives2023] \| aSHM target and high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]\|
29		-\|![FL](images/icons/FL_tier1.png) \|1 \| aSHM target and high-confidence FL gene \|
30		-\|![BL](images/icons/BL_tier2.png) \|2 \| aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@burkhardtClinicalRelevanceMolecular2022]\|
	24	+[[include:table1_BTG1.md]]
31	25
32	26	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
33	27

...	...	@@ -16,11 +16,7 @@ BTG2 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
16	16
17	17	## Relevance tier by entity
18	18
19		-\|Entity\|Tier\|Description \|
20		-\|:------:\|:----:\|--------------------------------------\|
21		-\|![BL](images/icons/BL_tier2.png) \|3 \| Retired, Failed QC[@loveGeneticLandscapeMutations2012]\|
22		-\|![DLBCL](images/icons/DLBCL_tier1.png) \|1 \| aSHM target and high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]\|
23		-\|![FL](images/icons/FL_tier1.png) \|1 \| aSHM target and high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]\|
	19	+[[include:table1_BTG2.md]]
24	20
25	21	## Warnings
26	22

...	...	@@ -11,10 +11,7 @@ One study reported BTK mutations in approximately 7% of FL and 11% of transforme
11	11
12	12	## Relevance tier by entity
13	13
14		-\|Entity\|Tier\|Description \|
15		-\|:------:\|:----:\|--------------------------\|
16		-\|![DLBCL](images/icons/DLBCL_tier1.png) \|1 \|high-confidence DLBCL gene[@albuquerqueEnhancingKnowledgeDiscovery2017; @reddyGeneticFunctionalDrivers2017]\|
17		-\|![FL](images/icons/FL_tier1.png) \|1 \|high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]\|
	14	+[[include:table1_BTK.md]]
18	15
19	16	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20	17